| Dr Sebastian R Schnellbacher, DO | |
|
550 Pope Ave, Fort Leavenworth, KS 66027-2332 | |
| (913) 684-6423 | |
| Not Available |
| Full Name | Dr Sebastian R Schnellbacher |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 550 Pope Ave, Fort Leavenworth, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164537759 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DOS-1121 (Hawaii) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | DOS1121 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sebastian R Schnellbacher, DO 550 Pope Ave, Fort Leavenworth, KS 66027-2332 Ph: () - | Dr Sebastian R Schnellbacher, DO 550 Pope Ave, Fort Leavenworth, KS 66027-2332 Ph: (913) 684-6423 |
News Archive
The Millennium Research Institute (MRI), a nonprofit national research center formed in 2010, and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego (UCSD) announced today five scientific articles co-authored by UCSD doctoral pharmacy students have been accepted by the Journal of Analytical Toxicology.
As the 9th Annual Health 2.0 Fall Conference rapidly approaches, Health 2.0 is excited to announce confirmed speakers at the inaugural Innovating Care Delivery Symposium. The day-long session features an agenda with executives and providers from some of the most progressive health systems in the nation, including UCLA, UCSF, Stanford, Henry Ford, and many others.
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.
The Harvard Clinical Research Institute (HCRI) announced today that the first patients have been enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial to investigate the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.
› Verified 5 days ago